MDMA therapy is an experimental treatment for post-traumatic stress disorder that combines doses of MDMA (commonly known as ecstasy or molly) with guided psychotherapy sessions. Rather than taking a daily medication, patients undergo a structured program of talk therapy sessions paired with two or three supervised experiences under the influence of MDMA. In Phase 3 clinical trials, 71% of participants who received MDMA-assisted therapy no longer met the diagnostic criteria for PTSD by the end of treatment, compared to about 48% who received therapy with a placebo.
How the Treatment Works
PTSD keeps people trapped in a cycle where traumatic memories trigger overwhelming fear, panic, or emotional shutdown. Traditional therapy asks patients to revisit those memories, but the distress can be so intense that people can’t stay engaged long enough to process what happened. MDMA changes the equation by reducing the fear response and increasing feelings of trust and emotional openness. This creates a window where patients can explore traumatic material with their therapist without becoming emotionally overwhelmed or shutting down.
The drug itself isn’t the treatment. It’s a tool that makes the therapy more effective. MDMA increases the release of serotonin, dopamine, and oxytocin, producing feelings of empathy, safety, and emotional closeness. For someone with PTSD, that neurochemical shift can make it possible to face memories they’ve spent years avoiding. The real therapeutic work happens in the conversations, emotional processing, and meaning-making that take place during and after the drug experience.
What the Treatment Program Looks Like
The full protocol spans several months and involves three distinct phases: preparation, dosing sessions, and integration. Two therapists are present throughout.
The program begins with three preparatory sessions before any MDMA is administered. These sessions build trust between the patient and the therapy team, set expectations for what the drug experience will feel like, and begin exploring the traumatic material that will be addressed later. This groundwork is considered essential. Walking into a psychedelic experience without preparation and a strong relationship with the therapists could be destabilizing rather than healing.
The dosing sessions themselves are long. Each one lasts about eight hours, with both therapists present the entire time. The patient lies down in a comfortable, living-room-style clinical setting, often wearing eyeshades and listening to music, while the MDMA takes effect. The therapists guide the experience but also follow the patient’s lead, allowing whatever emotions, memories, or insights arise to unfold naturally. Two or three of these dosing sessions are spaced several weeks apart over the course of treatment.
After each dosing session, three integration sessions help patients make sense of what they experienced. Traumatic memories may have surfaced in new ways, emotional breakthroughs may have occurred, and the integration sessions are where patients and therapists work together to translate those experiences into lasting psychological change. Without integration, the insights from an MDMA session can fade rather than solidify into genuine recovery.
Results From Clinical Trials
The strongest evidence comes from the MAPP1 and MAPP2 Phase 3 trials, which tested MDMA-assisted therapy in people with moderate to severe PTSD. In the MAPP2 trial, published in Nature Medicine, participants who received MDMA-assisted therapy saw their PTSD symptom scores drop by an average of 23.7 points on the standard clinical scale used to measure PTSD severity. Those who received the same therapy with a placebo instead of MDMA saw a drop of 14.8 points. The difference was statistically significant with what researchers consider a moderately large effect size.
The most striking number: 71.2% of MDMA-assisted therapy participants no longer qualified for a PTSD diagnosis at the end of the study. In the placebo-plus-therapy group, that figure was 47.6%. The placebo group still received extensive psychotherapy from the same trained therapists, so the comparison isn’t MDMA versus nothing. It’s MDMA-assisted therapy versus high-quality therapy alone. The fact that nearly half the placebo group also improved underscores that the therapy component matters enormously, but MDMA appears to significantly boost its effectiveness.
Common Side Effects
MDMA produces a predictable set of acute side effects during and shortly after dosing sessions. In the clinical trials, the most frequently reported effects were headache (72% of participants), jaw clenching and tightness (58%), decreased appetite (43%), insomnia (39%), and nausea (38%). Sweating, fatigue, and feeling unusually cold or hot were also common, each affecting roughly 20 to 30% of participants.
Some side effects reflect MDMA’s stimulant properties: muscle tightness (21%), dizziness (24%), feeling jittery (13%), and chest discomfort (11%). These generally resolve within hours to days after a session. On the psychiatric side, about 11% of participants reported nightmares, 6% experienced worsened depression in the days following a session, and 5% reported flashbacks or panic attacks. Restlessness affected about 15%.
Most of these effects are temporary and manageable within the supervised clinical setting. The eight-hour session format exists partly to ensure patients are monitored through the full duration of the drug’s effects and don’t leave until they’ve returned to a stable baseline.
Who Should Not Receive This Treatment
MDMA is a stimulant that raises blood pressure and heart rate, so the clinical trials excluded people with uncontrolled high blood pressure, a history of heart rhythm problems (including atrial fibrillation, ventricular arrhythmias, and certain conduction abnormalities), or heart conditions where a spike in cardiovascular activity could be dangerous. The FDA has noted that MDMA’s cardiac safety profile is not yet fully characterized, meaning long-term heart risks aren’t well understood.
On the psychiatric side, people with a history of psychotic disorders, bipolar I disorder, or dissociative identity disorder were excluded from trials. MDMA’s powerful effects on emotion, perception, and memory could destabilize these conditions. This doesn’t necessarily mean these individuals could never be treated, but it does mean there’s currently no safety data to support it.
Current Legal and Regulatory Status
MDMA remains a Schedule I controlled substance in the United States, meaning it is illegal outside of authorized research. As of 2024, no country has granted full regulatory approval for MDMA-assisted therapy as a standard medical treatment.
The closest it has come was in the U.S., where Lykos Therapeutics submitted a new drug application to the FDA. This was the first psychedelic drug development program to reach that stage. An FDA advisory committee met in June 2024 to review the application. The FDA acknowledged that participants in the trials experienced “clinically meaningful durable improvement” in PTSD symptoms, but raised concerns about factors that complicated interpretation of the data and flagged gaps in the cardiac safety assessment. The advisory committee voted against recommending approval, and the FDA subsequently declined to approve the drug, requesting additional data.
This does not mean MDMA therapy has been rejected permanently. The pathway forward likely involves additional clinical trials or data collection to address the FDA’s specific concerns. In the meantime, MDMA-assisted therapy is only available through authorized clinical trials or through expanded access programs in limited circumstances. Several other countries, including Australia, have moved toward allowing certain psychedelic therapies in controlled medical settings, though MDMA availability varies.
How It Differs From Other PTSD Treatments
Standard PTSD treatment typically involves ongoing therapy (such as prolonged exposure or cognitive processing therapy), daily medications like antidepressants, or both. These approaches work for many people but leave a substantial number with persistent symptoms. The clinical trials for MDMA-assisted therapy specifically enrolled people with moderate to severe PTSD, many of whom had not responded adequately to existing treatments.
The structure of MDMA therapy is fundamentally different from daily medication. Rather than taking a pill every day for months or years, patients receive MDMA on only two or three occasions across the entire treatment program. The drug is administered in a clinical setting under direct supervision, not prescribed for home use. This makes it closer to a procedural intervention than a traditional prescription. The total number of therapy sessions (preparation, dosing, and integration combined) spans roughly 12 to 15 sessions over several months, after which the treatment is complete. Whether the benefits persist long-term without additional sessions is still being studied.